- AU$787.56m
- AU$774.30m
- AU$104.73m
- 58
- 18
- 32
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 51.82 | ||
| PEG Ratio (f) | 0.88 | ||
| EPS Growth (f) | 144.44% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.43 | ||
| Price to Tang. Book | 10.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.76 | ||
| EV to EBITDA | 76.14 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.64% | ||
| Return on Equity | 8.17% | ||
| Operating Margin | 6.66% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 22.19 | 29.16 | 41.44 | 66.11 | 104.73 | 128.59 | 159.96 | 50.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +20.64 | +144.44 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
Directors
- David Williams NEC
- Robert Johnston CEO
- Jan Gielen CFO
- Joshua Cheetham OTH
- Robyn Elliott NED
- Christine Emmanuel NED
- Leon Hoare NED
- Andrew Lumsden NED
- David McQuillan NID
- Bruce Rathie NID (61)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 12th, 1998
- Public Since
- November 26th, 1998
- No. of Shareholders
- 17,619
- No. of Employees
- 282
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 690,842,991
- Address
- 2/320 Lorimer Street, MELBOURNE, 3207
- Web
- https://polynovo.com/
- Phone
- +61 800958289
- Auditors
- Ernst & Young
Upcoming Events for PNV
Polynovo Ltd Annual Shareholders Meeting
Similar to PNV
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
Atomo Diagnostics
Australian Stock Exchange - SEATS
FAQ
What is the Polynovo share price?
As of Today at 22:42 UTC, shares in Polynovo are trading at AU$1.14. This share price information is delayed by 15 minutes.
How has the Polynovo share price performed this year?
Shares in Polynovo last closed at AU$1.14 and the price had moved by -50.43% over the past 365 days. In terms of relative price strength the Polynovo share price has underperformed the ASX All Ordinaries Index by -54.29% over the past year.
What are the analyst and broker recommendations for Polynovo?
The overall consensus recommendation for Polynovo is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Polynovo dividend yield?
Polynovo does not currently pay a dividend.
Does Polynovo pay a dividend?
Polynovo does not currently pay a dividend.
When does Polynovo next pay dividends?
Polynovo does not currently pay a dividend.
How do I buy Polynovo shares?
To buy shares in Polynovo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Polynovo?
As of the previous close price of AU$1.14, shares in Polynovo had a market capitalisation of AU$787.56m.
Where are Polynovo shares listed?
Here are the trading details for Polynovo:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PNV
What kind of share is Polynovo?
Based on an overall assessment of its quality, value and momentum Polynovo is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Polynovo share price forecast for 2025?
The analyst consensus target price for shares in Polynovo is AU$2.16. That is 89.39% above the last closing price of AU$1.14.
Analysts covering Polynovo currently have a consensus Earnings Per Share (EPS) forecast of AU$0.01 for the next financial year.
Find out moreWhat is the trend in the Polynovo share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Polynovo. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -47.61%.
As of the last closing price of AU$1.14, shares in Polynovo were trading -33.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Polynovo PE Ratio?
The Polynovo PE ratio based on its reported earnings over the past 12 months is 51.82. The shares last closed at AU$1.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Polynovo?
Polynovo's management team is headed by:
- David Williams - NEC
- Robert Johnston - CEO
- Jan Gielen - CFO
- Joshua Cheetham - OTH
- Robyn Elliott - NED
- Christine Emmanuel - NED
- Leon Hoare - NED
- Andrew Lumsden - NED
- David McQuillan - NID
- Bruce Rathie - NID